ANGIODYNAMICS INC ANGO
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
-1.82
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $292.5M | -$34.0M | $157.7M | -$14.6M | $183.0M |
| 2024 | $303.9M | -$184.3M | $154.7M | -$30.7M | $205.6M |
| 2023 | $338.8M | -$52.4M | $174.2M | -$3.7M | $378.3M |
| 2022 | $316.2M | -$26.5M | $165.7M | -$11.5M | $424.5M |
| 2021 | $291.0M | -$31.5M | $156.8M | $18.9M | $439.5M |
| 2020 | $264.2M | -$166.8M | $150.3M | -$21.8M | $454.9M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.82 (distress)
- Working capital / assets 0.329
- Retained earnings / assets -1.532
- EBIT / assets -0.143
- Equity / liabilities 1.883
Source: SEC EDGAR filings · CIK 0001275187 · as of 2025-05-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.